144 related articles for article (PubMed ID: 9465942)
21. Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.
Fahrenkamp AG; Wibbeke C; Winde G; Ofner D; Böcker W; Fischer-Colbrie R; Schmid KW
Virchows Arch; 1995; 426(4):361-7. PubMed ID: 7599788
[TBL] [Abstract][Full Text] [Related]
22. Identification of gastroenteropancreatic neuroendocrine cells in normal and neoplastic human tissue with antibodies against synaptophysin, chromogranin A, secretogranin I (chromogranin B), and secretogranin II.
Wiedenmann B; Waldherr R; Buhr H; Hille A; Rosa P; Huttner WB
Gastroenterology; 1988 Nov; 95(5):1364-74. PubMed ID: 3139487
[TBL] [Abstract][Full Text] [Related]
23. Immunoreactivities for chromogranin A and B, and secretogranin II in the guinea pig entero-endocrine system: cellular distributions and intercellular heterogeneities.
Cetin Y; Grube D
Cell Tissue Res; 1991 May; 264(2):231-41. PubMed ID: 1878943
[TBL] [Abstract][Full Text] [Related]
24. [Neuroendocrine differentiation in adenocarcinoma of prostate during combined androgen blockade therapy: a case report].
Kitamoto K; Hayashi T; Tamada S; Ezaki K; Kawashima H; Sugimura K; Nakatani T
Hinyokika Kiyo; 2005 Jan; 51(1):33-5. PubMed ID: 15732339
[TBL] [Abstract][Full Text] [Related]
25. New perspective in the management of neuroendocrine differentiation in prostate adenocarcinoma.
Sciarra A; Cardi A; Dattilo C; Mariotti G; Di Monaco F; Di Silverio F
Int J Clin Pract; 2006 Apr; 60(4):462-70. PubMed ID: 16620361
[TBL] [Abstract][Full Text] [Related]
26. Effect of short- and long-term physical activities on circulating granin protein levels.
Røsjø H; Opstad PK; Hoff JE; Godang K; Christensen G; Stridsberg M; Omland T
Regul Pept; 2013 Aug; 185():14-9. PubMed ID: 23816467
[TBL] [Abstract][Full Text] [Related]
27. Topology of chromogranin A and secretogranin II in the rat anterior pituitary: potential marker proteins for distinct secretory pathways in gonadotrophs.
Watanabe T; Uchiyama Y; Grube D
Histochemistry; 1991; 96(4):285-93. PubMed ID: 1723974
[TBL] [Abstract][Full Text] [Related]
28. Measurements of secretogranins II, III, V and proconvertases 1/3 and 2 in plasma from patients with neuroendocrine tumours.
Stridsberg M; Eriksson B; Janson ET
Regul Pept; 2008 Jun; 148(1-3):95-8. PubMed ID: 18448176
[TBL] [Abstract][Full Text] [Related]
29. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.
Jongsma J; Oomen MH; Noordzij MA; Van Weerden WM; Martens GJ; van der Kwast TH; Schröder FH; van Steenbrugge GJ
Cancer Res; 2000 Feb; 60(3):741-8. PubMed ID: 10676662
[TBL] [Abstract][Full Text] [Related]
30. Potential clinical value of circulating chromogranin A in patients with prostate carcinoma.
Berruti A; Dogliotti L; Mosca A; Gorzegno G; Bollito E; Mari M; Tarabuzzi R; Poggio M; Torta M; Fontana D; Angeli A
Ann Oncol; 2001; 12 Suppl 2():S153-7. PubMed ID: 11762344
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features.
Alberti C
G Chir; 2010; 31(11-12):568-74. PubMed ID: 21232206
[TBL] [Abstract][Full Text] [Related]
32. Analysis of chromogranin/secretogranin messenger RNAs in human pituitary adenomas.
Lloyd RV; Jin L
Diagn Mol Pathol; 1994 Mar; 3(1):38-45. PubMed ID: 8162254
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.
Bonkhoff H; Stein U; Remberger K
Virchows Arch A Pathol Anat Histopathol; 1993; 423(4):291-4. PubMed ID: 7694424
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical localization of chromogranin A and secretogranin II in female rat gonadotropes.
Watanabe T; Azuma T; Banno T; Jeziorowski T; Ohsawa Y; Waguri S; Grube D; Uchiyama Y
Arch Histol Cytol; 1998 May; 61(2):99-113. PubMed ID: 9650885
[TBL] [Abstract][Full Text] [Related]
35. Purification, pH-dependent conformational change, aggregation, and secretory granule membrane binding property of secretogranin II (chromogranin C).
Park HY; So SH; Lee WB; You SH; Yoo SH
Biochemistry; 2002 Jan; 41(4):1259-66. PubMed ID: 11802725
[TBL] [Abstract][Full Text] [Related]
36. [Relationship of neuroendocrine differentiation to biological behavior of prostate cancer].
Wu XL; Huang KT; Chen W; Chen L; Dong L; Yu ZX
Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):472-5. PubMed ID: 19567097
[TBL] [Abstract][Full Text] [Related]
37. Secretogranin II is overexpressed in advanced prostate cancer and promotes the neuroendocrine differentiation of prostate cancer cells.
Courel M; El Yamani FZ; Alexandre D; El Fatemi H; Delestre C; Montero-Hadjadje M; Tazi F; Amarti A; Magoul R; Chartrel N; Anouar Y
Eur J Cancer; 2014 Nov; 50(17):3039-49. PubMed ID: 25307750
[TBL] [Abstract][Full Text] [Related]
38. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma.
Grobholz R; Bohrer MH; Siegsmund M; Jünemann KP; Bleyl U; Woenckhaus M
Pathol Res Pract; 2000; 196(5):277-84. PubMed ID: 10834383
[TBL] [Abstract][Full Text] [Related]
39. Distribution of chromogranin A and secretogranin I (chromogranin B) in neuroendocrine cells and tumors.
Lloyd RV; Cano M; Rosa P; Hille A; Huttner WB
Am J Pathol; 1988 Feb; 130(2):296-304. PubMed ID: 3341449
[TBL] [Abstract][Full Text] [Related]
40. Neuroendocrine cell type-specific and inducible expression of chromogranin/secretogranin genes: crucial promoter motifs.
Mahata SK; Mahapatra NR; Mahata M; O'Connor DT
Ann N Y Acad Sci; 2002 Oct; 971():27-38. PubMed ID: 12438085
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
